{
  "id": 5729938,
  "title": "Denali Therapeutics director sells $261,928 in stock",
  "url": "https://urgent.news/2026/09/05/denali-therapeutics-director-sells-261-928-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-05T06:00:59.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/denali-therapeutics-director-sells-261928-in-stock-93CH-4890168"
  },
  "original_language": "en",
  "account": null,
  "summary": "Denali Therapeutics Inc. (NASDAQ:DNLI) director Nancy Thornberry sold 11,439 shares of the company's common stock on September 2, 2026, for a total of $261,928. The shares were sold under a Rule 10b5-1 trading plan, with prices ranging from $22.54 to $23.85 per share. As of the sale, DNLI stock was trading at $22.28, up 35% year-to-date and 44% over the past year, though still 18% below its 52-week high of $27.30. Thornberry now directly holds 19,686 shares of Denali Therapeutics common stock, including 6,408 unvested Restricted Stock Units (RSUs). Despite these recent sales, the company's stock saw an increase in after-hours trading following the announcement of its first approved medicine, AVLAYAH, which generated $3.6 million in its initial full commercial quarter following FDA approval.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Crowdstrike CEO George Kurtz sells $4.16m in shares",
        "url": "https://urgent.news/2026/09/05/crowdstrike-ceo-george-kurtz-sells-4-16m-in-shares",
        "published": "2026-09-05T00:34:52.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}